

## Digestive Diseases Research Seminar

Presented by Yale School of Medicine, Department of Internal Medicine, and Section of Digestive Diseases

# Non-invasive assessment of clinically significant portal hypertension in patients with NASH cirrhosis

Anahita Rabiee, MD

Fellow of Medicine, Department of Internal Medicine (Digestive Diseases)  
Yale School of Medicine

Tuesday, June 14, 2022

5:00 - 6:00 pm

<https://zoom.us/j/96996768379?pwd=cUJVSXFSTVIZIF1NE9RR1JTUllpZz09&from=addon>

Host: Guadalupe Garcia-Tsao, MD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29452) to 203-442-9435.

**There is no corporate support for this activity. Accreditation:** The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Portal pressure is determined by the hepatic venous pressure gradient (HVPG) and is the main driver of cirrhosis decompensation (i.e. development of ascites, variceal hemorrhage, or hepatic encephalopathy). In patients with compensated cirrhosis, "clinically-significant portal hypertension" (CSPH), defined as HVPG of  $\geq 10$ , is the main predictor of decompensation [1]. In addition to its prognostic value, the stratification of patients into those with and without CSPH has important clinical implications as it has been shown that, in patients with compensated cirrhosis and CSPH, decompensation can be prevented by the use of non-selective beta blockers (NSBB) [2]. However, obtaining HVPG requires an invasive procedure, and is not readily available in daily clinical practice. Liver stiffness measurement (LSM) obtained by transient elastography (TE) has been shown to be a useful non-invasive alternative to predict the presence of CSPH in patients with compensated cirrhosis [3]. However, translation of these findings to the NASH population has remained a major challenge; first, NASH has been under-represented in previous studies (which mainly focused on hepatitis C and alcohol); second, there are technical difficulties with obtaining accurate TE in obese patients [4], and third, there is an increase in LSM in the setting of severe steatohepatitis [5]. With the growing population of NASH patients, this knowledge gap represents a critical unmet need in the care of patients with NASH cirrhosis. **Objectives:** Review of the current non-invasive models to identify CSPH in patients with compensated cirrhosis; 2. Validation of previous prediction models for CSPH in patients with compensated NASH cirrhosis; 3. Development and external validation of a new lab-based model to predict CSPH in patients with NASH cirrhosis. **References:** 1. Ripoll, C., et al., Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients with Compensated Cirrhosis. *Gastroenterology*, 2007. 133(2): p. 481-488. 2. Villanueva, C., et al.,  $\beta$  blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomized, double-blind, placebo-controlled, multicenter trial. *The Lancet*, 2019. 393(10181): p. 1597-1608. 3. Abralides, J.G., et al., Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study; *Hepatology*, Vol. XX, No. X, 2016 Abralides et al. *Hepatology*, 2016. 64(6): p. 2173-2184. 4. Castéra, L., et al., Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. *Hepatology* (Baltimore, Md.), 2010. 51(3): p. 828-835. 5. Petta, S., et al., The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease: STEATOHEPATITIS/METABOLIC LIVER DISEASE. *Hepatology*, 2015. 62(4): p. 1101-1110. **Faculty Disclosures:** Faculty for this educational activity have no relevant financial relationship with ineligible companies to disclose. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**